Skip to content

"Intramuscular Ketamine use as an Antisuicidal drug"

An Open label Prospective, Interventional study of effect of fixed dose (0.5mg/kg) Intra-muscular Ketamine on patients having suicidal ideations attending tertiary care hospital.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/09/045713
Enrollment
30
Registered
2022-09-20
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F322- Major depressive disorder, singleepisode, severe without psychotic features

Interventions

Intervention1: Intramuscular injection Ketamine: Intramuscular Ketamine (0.5 mg per kg) will be on patients having suicidal ideations (MADRS SI more than 3) and repeat MADRS scale applied on 2hours po

Sponsors

NIL
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Having suicidal ideations (MADRS-SI score >3) 2. Who gave consent

Exclusion criteria

Exclusion criteria: 1. Present diagnosis or antecedents of clinically relevant cardiovascular disorders such as stroke, heart attack, etc. 2. Present or past diagnosis of glaucoma, intracranial hypertension. 3. Current diagnosis of schizophrenia as defined in the ICD-11. 4. Patients with any known hypersensitivity to ketamine. 5. patients who are hemodynamically unstable. 6. Delirious patients. 7. Pregnancy.

Design outcomes

Primary

MeasureTime frame
MADRS SI score, vitals, adverse events are to be checked to see effectiveness and safety of intramuscular ketamine (0.5 mg/k)Timepoint: baseline, 2 hours post injection, then on day 1,3,7,14,21,28.(1 month follow up)

Secondary

MeasureTime frame
not applicableTimepoint: not applicable

Countries

India

Contacts

Public ContactMalika Sanspara

GMERS hospital, Gotri

hod.psy.gotri@gmail.com9824060683

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026